Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide dose-escalation phase II study in dumping syndrome
NL-OMON36982Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of pasireotide LAR in dumping syndrome, sponsored by Novartis. Started Jan 2013; status: active, not recruiting.
02
Drugs
pasireotide LAR
03
Conditions
dumping syndrome
Beyond the preview
Go deeper on NL-OMON36982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36982.